Trial Profile
A Phase 1, Open-Label, Single-Dose, Pharmacokinetic and Safety Study of E7080 (24 mg) Administered to Subjects With Mild, Moderate, and Severe Renal Impairment and to Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Apr 2015
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary)
- Indications Adenocarcinoma; Endometrial cancer; Glioma; Liver cancer; Lymphoma; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cancer; Solid tumours; Thyroid cancer
- Focus Pharmacokinetics
- Sponsors Eisai Inc
- 28 Jul 2014 New trial record